Want to see JP:4582 full AI Analyst Report?
4582 Stock Chart & Stats
¥64.00
¥1.00(1.52%)
At close: 4:00 PM EDT
¥64.00
¥1.00(1.52%)
Day’s Range― - ―
52-Week Range¥55.00 - ¥229.00
Previous CloseN/A
Volume398.00K
Average Volume (3M)603.91K
Market Cap
¥4.65B
Enterprise Value¥5.12K
Total Cash (Recent Filing)¥977.18M
Total Debt (Recent Filing)¥832.50M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-100.06
Shares Outstanding80,246,460
10 Day Avg. Volume413,980
30 Day Avg. Volume603,910
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)3.55
Price to Sales (P/S)3.46
P/FCF Ratio-0.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginA consistently high gross margin indicates that the company’s products retain substantial value after direct production costs. Although operating expenses currently absorb that contribution, the margin provides a foundation for potential earnings recovery if revenue stabilizes and the broader cost burden is reduced.
Specialty Pharmaceutical FocusA focused specialty-pharmaceutical and oncology orientation gives Symbio a defined business identity within prescription medicines. Its activities cover development, approvals, commercialization, and lifecycle management, creating an integrated platform for managing products across their commercial lives.
Meaningful Asset BaseA meaningful asset base provides some underlying resources to support ongoing operations and product activities despite current financial pressure. This does not eliminate leverage concerns, but it offers a more substantial operating foundation than a balance sheet dominated solely by accumulated losses.
Bears Say
Persistent Revenue DeclineMulti-year revenue contraction, culminating in a sharp 2025 decline, signals weakening commercial scale and reduces the company’s ability to spread operating costs across sales. Continued top-line pressure can also limit investment capacity for development, commercialization, and future product growth.
Deepening UnprofitabilityThe shift from positive profitability to deeply negative operating and net margins indicates that high gross margins are being overwhelmed by costs outside direct production. Sustained losses can erode equity, constrain strategic choices, and make a durable earnings recovery more difficult.
Cash Burn And Rising LeverageNegative operating and free cash flow show that the business is not currently funding itself from operations. Combined with newly increased debt and compressed equity, persistent cash burn raises reliance on external financing and reduces flexibility if losses continue.
Symbio Pharmaceuticals Limited News
4582 FAQ
What was Symbio Pharmaceuticals Limited’s price range in the past 12 months?
Symbio Pharmaceuticals Limited lowest stock price was ¥55.00 and its highest was ¥229.00 in the past 12 months.
What is Symbio Pharmaceuticals Limited’s market cap?
Symbio Pharmaceuticals Limited’s market cap is ¥4.65B.
When is Symbio Pharmaceuticals Limited’s upcoming earnings report date?
Symbio Pharmaceuticals Limited’s upcoming earnings report date is Oct 29, 2026 which is in 47 days.
How were Symbio Pharmaceuticals Limited’s earnings last quarter?
Symbio Pharmaceuticals Limited released its earnings results on Jul 30, 2026. The company reported -¥15 earnings per share for the quarter.
Is Symbio Pharmaceuticals Limited overvalued?
According to Wall Street analysts Symbio Pharmaceuticals Limited’s price is currently Overvalued.
Does Symbio Pharmaceuticals Limited pay dividends?
Symbio Pharmaceuticals Limited does not currently pay dividends.
What is Symbio Pharmaceuticals Limited’s EPS estimate?
Symbio Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Symbio Pharmaceuticals Limited have?
Symbio Pharmaceuticals Limited has 80,246,460 shares outstanding.
What happened to Symbio Pharmaceuticals Limited’s price movement after its last earnings report?
Symbio Pharmaceuticals Limited reported an EPS of -¥15 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Symbio Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in JP:4582
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Symbio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
Technical Analysis
Solasia Pharma KK
―
Wakamoto Pharmaceutical Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Medrx Co., Ltd.
―